<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883568</url>
  </required_header>
  <id_info>
    <org_study_id>APPROACH-OA-P01</org_study_id>
    <nct_id>NCT03883568</nct_id>
  </id_info>
  <brief_title>A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis</brief_title>
  <acronym>APPROACH</acronym>
  <official_title>A 2-year Multicentre, EU, Exploratory Study Without Therapeutic Benefit in Patients With Knee Osteoarthritis to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis by Use of Clinical, Imaging, and Biochemical (Bio)Markers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F.P.J.G. Lafeber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complexo Hospitalario Universitario de A Coruña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Despite a large and growing disease burden in osteoarthritis (OA), many&#xD;
      pharmaceutical companies have abandoned OA drug development. This is mainly due to the lack&#xD;
      of appropriate outcome measures that can robustly identify patients that can benefit from a&#xD;
      specific therapy. Different phenotypes of OA may benefit from different types of treatment.&#xD;
      Therefore, novel markers to identify selected phenotypes of osteoarthritis may encourage drug&#xD;
      development.&#xD;
&#xD;
      Objective: To prospectively describe in detail pre-identified progressing phenotypes of&#xD;
      patients with knee OA by use of conventional and novel clinical, imaging, and biochemical&#xD;
      (bio)markers, and to validate and refine a predictive model for these (and new) progressing&#xD;
      phenotypes based on these markers.&#xD;
&#xD;
      Study design: APPROACH is an exploratory, European, five-centre, 2-year prospective&#xD;
      follow-up, cohort study, with extensive measurements. In this study patients are treated&#xD;
      according to regular care by their own physician with no study related treatment prescribed.&#xD;
      Study related diagnostic and/or monitoring procedures are applied to the patients.&#xD;
&#xD;
      Study population: Patients with tibiofemoral knee osteoarthritis, according to the clinical&#xD;
      ACR classification criteria, pre-identified based on demographic (e.g. age), clinical (e.g.&#xD;
      Pain NRS) and tissue structure (e.g. radiographic joint space width) parameters.&#xD;
&#xD;
      Main study parameters/endpoints: Joint tissue structure based on radiographs, MRI, and&#xD;
      biochemical (bio)markers as well as symptoms (pain, function) and quality of life by&#xD;
      questionnaires.&#xD;
&#xD;
      Secondary parameters: A multitude of (novel and conventional) clinical, imaging, and&#xD;
      biochemical parameters related to osteoarthritis.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The participants will not have any direct benefit from their participation in&#xD;
      this study other than that their OA is maximally diagnosed and followed in detail for up to 2&#xD;
      years (screening, baseline, 6 months, 12 months, 24 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will stay in the hospital for 4-5 hours per visit (for screening about 30 min) for&#xD;
      physical examination, blood draw, MRI scans, radiographs of knees and hands (only at baseline&#xD;
      and 24 months), CT scan of the knee (only at baseline and 24 months), low radiation whole&#xD;
      body CT scan (only at baseline and 24 months), HandScan (only at baseline and 24 months),&#xD;
      motion analysis, and performance based tests. They will be asked to fill out questionnaires&#xD;
      about knee, hand and hip osteoarthritis, and about general health and pain. The patient&#xD;
      council in the consortium indicated that the load is acceptable. The patient council will be&#xD;
      involved in the execution of the study. The assumed risk is minimal for an individual patient&#xD;
      and minimal compared to the contribution to the development of knowledge of their disease.&#xD;
      These risks include minimal events due to blood sampling itself (such as hematoma or&#xD;
      localized bleeding), radiation exposure by radiographic imaging techniques (with a minimal&#xD;
      increased healthcare risk), and exposure to MRI techniques (without known risks and without&#xD;
      use of contrast agents).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OA structural progression of the index knee</measure>
    <time_frame>over two years</time_frame>
    <description>radiographic joint space width in mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OA pain progression of the index knee</measure>
    <time_frame>over two years</time_frame>
    <description>increase in points in Knee Osteoarthritis Outcome Score for pain (0-100; 0 worst, 100 best condition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OA progression of the index knee</measure>
    <time_frame>over two years</time_frame>
    <description>structural progression (e.g. cartilage volume on MRI in mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OA progression</measure>
    <time_frame>over two years</time_frame>
    <description>structural progression (biochemical markers in units/ml in blood and urine)</description>
  </secondary_outcome>
  <enrollment type="Actual">297</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, blood DNA, blood RNA, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tibiofemoral knee osteoarthritis, according to the clinical ACR&#xD;
        classification criteria, pre-identified based on demographic (e.g. age), clinical (e.g.&#xD;
        Pain NRS) and tissue structure (e.g. radiographic joint space width) parameters.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained.&#xD;
&#xD;
          2. Ambulatory (able to walk unassisted)&#xD;
&#xD;
          3. At least 18 years of age&#xD;
&#xD;
          4. Capable of understanding the study&#xD;
&#xD;
          5. Capable of writing and reading in local language&#xD;
&#xD;
          6. Predominantly tibiofemoral knee osteoarthritis and satisfy the clinical classification&#xD;
             criteria of the American College of Rheumatology (ACR): Knee pain and three of the&#xD;
             following criteria: over 50 years age, less than 30 minutes of morning stiffness,&#xD;
             crepitus on active motion, bony tenderness, bony enlargement, or no palpable warmth.&#xD;
&#xD;
          7. Highest probability to progress based on the algorithm based on the following&#xD;
             parameters:&#xD;
&#xD;
               -  Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire&#xD;
&#xD;
               -  BMI (in recording height and weight)&#xD;
&#xD;
               -  Pain NRS of the index knee at the moment of the screening visit&#xD;
&#xD;
               -  Pain NRS of the index knee during the last week before the screening visit&#xD;
&#xD;
               -  Age&#xD;
&#xD;
               -  Gender&#xD;
&#xD;
               -  KIDA parameters of the index knee, based on standardized weight-bearing (KIDA)&#xD;
                  radiograph, measured &lt; 3 months (patients with a Joint Space Width (JSW) &lt; 2 mm&#xD;
                  of the index knee will not be included)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          8. Not being able to comply to the protocol&#xD;
&#xD;
          9. Participating in a trial with local therapeutic intervention for index knee OA&#xD;
             (pharmaceutical or surgical) or systemic Disease Modifying OsteoArthritic Drugs&#xD;
             (DMOADs) or potential DMOADs treatments for OA at the same time or within the past 6&#xD;
             months or anticipated in the forthcoming; participation in non-interventional&#xD;
             registries or epidemiological studies is allowed.&#xD;
&#xD;
         10. Surgery of the index knee in the past 6 months (to avoid interferences with imaging)&#xD;
&#xD;
         11. Scheduled or expected surgery of the index knee in the next 2 years (to avoid&#xD;
             interferences with imaging)&#xD;
&#xD;
         12. Pregnancy (child bearing woman) because of imaging (radiation and MRI, risks)&#xD;
&#xD;
         13. Predominantly patellar femoral knee OA (clinical judgment)&#xD;
&#xD;
         14. The following secondary osteoarthritis of the knee: clinically significant deformities&#xD;
             of the lower limbs (varus &gt;10°, valgus &gt;10°), septic arthritis, inflammatory joint&#xD;
             disease, gout, major chondrocalcinosis (pseudogout), Paget's disease of the bone,&#xD;
             ochronosis, acromegaly, haemochromatosis, Wilson's disease, rheumatic symptoms due to&#xD;
             malignancies, primary osteochondromatosis, osteonecrosis, osteochondritis dissecans,&#xD;
             haemophilia&#xD;
&#xD;
         15. Generalized pain syndrome, for example fibromyalgia&#xD;
&#xD;
         16. Patients with contra indication to MRI or CT&#xD;
&#xD;
         17. Hip replacement or expected hip replacement within 6 months&#xD;
&#xD;
         18. Osteosynthesis material near the knee joint&#xD;
&#xD;
         19. Self-reported severe Intervertebral disc (IVD) degeneration or facet OA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Floris PJ Lafeber, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint-Antoine hospital, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SERGAS</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>F.P.J.G. Lafeber</investigator_full_name>
    <investigator_title>Professor, director of research</investigator_title>
  </responsible_party>
  <keyword>phenotypes</keyword>
  <keyword>(bio)markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

